Related Experiment Videos
HBV and liver cancer.
1Alice Ho Miu Ling Nethersole Hospital and The Chinese University of Hong Kong, Hong Kong, SAR, China.
The Medical Journal of Malaysia
|August 20, 2005
Summary
Hepatitis B virus (HBV) infection significantly increases liver cancer risk. Prevention through universal HBV vaccination and early treatment of chronic hepatitis B are crucial for reducing hepatocellular carcinoma (HCC) incidence.
Area of Science:
- Hepatology
- Virology
- Oncology
Background:
- Hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC).
- Chronic HBV infection, particularly with active liver disease and cirrhosis, elevates HCC risk.
- HCC incidence rises with age and is more prevalent in males.
Purpose of the Study:
- To review the epidemiological evidence linking HBV infection to liver cancer.
- To explore the molecular mechanisms and contributing factors in HBV-induced hepatocarcinogenesis.
- To discuss current prevention strategies and therapeutic approaches for HBV-related HCC.
Main Methods:
- Epidemiological data analysis on HBV and HCC incidence.
- Review of molecular studies on HBV-host interactions and oncogenesis.
- Assessment of vaccination programs and antiviral therapies' impact on HCC.
Main Results:
- Universal HBV vaccination programs, like Taiwan's, have significantly reduced pediatric HCC rates.
- HBV DNA integration and the HBX protein are implicated in altering cell proliferation and apoptosis.
- Viral load, HBV genotypes, co-infections, and host factors influence HCC development.
Conclusions:
- Preventing HBV infection via vaccination and effectively treating chronic hepatitis B are paramount for HCC prevention.
- Early HCC detection through surveillance and prompt curative therapy improve patient outcomes.
- While antiviral agents show benefit, they are effective in a minority; prevention remains key.